- Home
- ITOS
as 05-20-2024 1:32pm EST
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 646.6M | IPO Year: | 2020 |
| Target Price: | $33.75 | AVG Volume (30 days): | 408.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.78 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.20 - $18.75 | Next Earning Date: | 05-10-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 83.03% | Revenue Growth (next year): | -64.45% |
Share on Social Networks:
Latest iTeos Therapeutics Inc. News
ITOS Breaking Stock News: Dive into ITOS Ticker-Specific Updates for Smart Investing
MT Newswires
7 days ago
HC Wainwright Adjusts Price Target on iTeos Therapeutics to $46 From $44, Maintains Buy Rating
MT Newswires
10 days ago
Wedbush Adjusts iTeos Therapeutics' Price Target to $21 From $18, Maintains Outperform Rating
MT Newswires
10 days ago
iTeos Therapeutics Q1 Net Loss Widens; Initiates $120 Million Registered Direct Offering -- Shares Jump
GlobeNewswire
10 days ago
iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates
GlobeNewswire
10 days ago
iTeos Therapeutics Announces $120 Million Registered Direct Offering
BioPharma Dive
10 days ago
iTeos shares jump on TIGIT update; Acelyrin swaps CEOs
GlobeNewswire
a month ago
iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024
GlobeNewswire
2 months ago